novo nordisk eli lilly - Search News

Order byBest matchMost fresh

News

Eli Lilly, Novo Nordisk

Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly and Company (LLY) for long-term growth.

Continue reading

· 56m · on MSN

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

1hon MSN

Wegovy News Pushes Novo Nordisk Stock Higher

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

3hon MSN

Novo Nordisk to offer Ozempic at $499 per month to eligible US customers

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Fierce Pharma2h

Novo Nordisk unveils $499 cash-pay Ozempic offering amid continued compounder competition

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

2d

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

3h

Novo Nordisk stock soar 5% today: here’s why analysts are bullish

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results